medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2010, Number 04

<< Back

Ginecol Obstet Mex 2010; 78 (04)

Clinical practice guideline. Ovarian cancer: diagnosis and treatment

Aranda-Flores C, Arteaga-Gómez AC, Muñoz-González D

Language: Spanish
References: 18
Page: 415-435
PDF size: 580.19 Kb.


ABSTRACT

No abstract


REFERENCES

  1. Anónimo. Registro hospitalario de cáncer, Compendio de cáncer 2000-2004. Cancerología 2007;2:200-87.

  2. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.

  3. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25:2928-37.

  4. Kumpulainen S, Kuoppala T, Leminen A, Komulainen M, Puistola U, Sankila R, et al. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: A prospective nationwide survey in Finland. Acta Obstet Gynecol Scand 2007;86:610-4.

  5. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk after the use of ovulationstimulating drugs. Obstet Gynecol 2004;103:1194-203.

  6. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: A critical review of the literature. Fertil Steril 2006;85:819-26.

  7. Fortin A, Morice P, Thoury A, Camatte S, Dhainaut C, Madelenat P. Impact of infertility drugs after treatment of borderline ovarian tumors: Results of a retrospective multicenter study. Fertil Steril 2007;87:591-6.

  8. Kashyap S, Davis OK. Ovarian cancer and fertility medications: A critical appraisal. Semin Reprod Med 2003;21:65-71.

  9. Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum ca-125. J Natl Cancer Inst 2007;99:1706-14.

  10. Geomini PM, Kluivers KB, Moret E, Bremer GL, Kruitwagen RF, Mol BW. Evaluation of adnexal masses with three-dimensional ultrasonography. Obstet Gynecol 2006;108:1167-75.

  11. Lykins EL, Pavlik EL, Andrykowski MA. Validity of self-reports of return for routine repeat screening in an ovarian cancer screening program. Cancer Epidemiol Biomarkers Prev 2007;16:490-3.

  12. Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol 2008;111:179-87.

  13. Cusido M, Balaguero L, Hernández G, Falcón O, Rodríguez-Escudero FJ, Vargas JA, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol 2007;104:617-22.

  14. Fauvet R, Poncelet C, Boccara J, Descamps P, Fondrinier E, Darai E. Fertility after conservative treatment for borderline ovarian tumors: A French multicenter study. Fertil Steril 2005;83:284-90; quiz 525-286.

  15. Lackman F, Carey MS, Kirk ME, McLachlin CM, Elit L. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants. Gynecol Oncol 2003;90:407-12.

  16. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecol Oncol 2006;101:255-60.

  17. Desfeux P, Camatte S, Chatellier G, Blanc B, Querleu D, Lecuru F. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005;98:390-5.

  18. Jordan SJ, Green AC, Whiteman DC, Webb PM. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol 2007;107:223-30.




2020     |     www.medigraphic.com